Latest & Greatest

Latest & Greatest

Recent developments in the field of hematology/oncology, including drug approvals, policy updates, and clinical trial results

Daratumumab and Hyaluronidase-fihj Combination Approved for Relapsed/Refractory MM

The FDA has approved daratumumab and hyaluronidase-fihj, in combination with pomalidomide and dexamethasone (Pd), for the treatment of patients with relapsed or refractory MM....

FDA Supports Inclusion of Pregnant and Breastfeeding Women in Clinical Trials

Officials at the FDA have announced their commitment to work with other regulators and industry to support the inclusion of pregnant and lactating women...

FDA Committee Votes Against Approval of Roxadustat for Anemia of Chronic Kidney Disease

The FDA’s Cardiovascular and Renal Drugs Advisory Committee (CRDAC) has decided not to recommend the approval of roxadustat for the treatment of patients with...

Cancer Death Rates Fell 1.4% More in Early Medicaid Expansion States

According to a new study published in the Journal of the National Cancer Institute, cancer death rates declined more sharply in U.S. states that...

ALLO-605 Receives FDA Fast Track Designation for Relapsed/Refractory MM

The U.S. Food and Drug Administration (FDA) has granted fast track designation to ALLO-605 for the treatment of adult patients with relapsed or refractory...

FDA Recommends Expanding Clinical Trial Eligibility for Patients with Incurable Cancers

The FDA has issued draft guidance for expanding investigational clinical trial options for patients with incurable cancers, encouraging sponsors to waive rules requiring patients...

Dabigatran Etexilate Approved for Children with VTE

The U.S. Food and Drug Administration (FDA) has approved dabigatran etexilate oral pellets for the treatment of children ages three months to 12 years...

One-Quarter of Americans Covered Under Medicaid During the Pandemic

A recent government report revealed that nearly 10 million Americans enrolled in Medicaid during the COVID-19 pandemic, with a record 80 million people –...

Orelabrutinib Receives Breakthrough Therapy Designation for Mantle Cell Lymphoma

The FDA has granted breakthrough therapy designation to the selective Bruton tyrosine kinase inhibitor orelabrutinib for the treatment of patients with relapsed/refractory mantle cell...

Gay and Bisexual Men Now Eligible to Donate Blood in the U.K.

The National Health Service (NHS) has announced that gay and bisexual men who have been in monogamous relationships for at least three months can...
Advertisement

Current Issue

September 2021 Volume 7 Issue 11

This issue discusses fertility preservation for young patients with cancer, reviews treatment options for primary immune thrombocytopenia, and more.

Block title